Company Overview and News
KUALA LUMPUR: Uzma Bhd , Aeon Credit Service (M) Bhd , EcoFirst Consolidated Bhd and Pantech Group Holdings Bhd are among the stocks to watch on Monday, according to JF Apex Research.
KUALA LUMPUR: Pantech Group Holdings Bhd ’s (Pantech) net profit for the financial year ended Feb 28, 2018, jumped to RM45.52mil from RM28.4mil recorded previously.
KUALA LUMPUR: Kenanga Investment Bank Research has upgraded Pantech Group Holdings Bhd to an “outperform” with a higher target price of 75 sen and also revised FY18-19E earnings by 14% following the strong 1Q18 results.
KUALA LUMPUR: The Federal Land Development Authority (Felda) has confirmed that the Rajawali Group has secured the Indonesian authorities’ approval to sell a non-controlling stake in Indonesian palm oil company PT Eagle High Plantations Tbk for US$505.4 million (RM2.24 billion) to Felda.
KUALA LUMPUR: While views may be divided over whether Koperasi Permodalan Felda Malaysia Bhd’s (KPF) sale of five million shares in Felda Global Ventures Holdings Bhd (FGV) is anything out of the ordinary, the move certainly raises eyebrows.
MarketWrap: A gauge of global equity markets climbed to a one-week high on Tuesday, lifted by rising commodity prices and a strong bounce in Europe, while solid corporate earnings helped drive share prices higher. Wall Street rose after a raft of stronger-than-expected results from UnitedHealth Group Inc, Netflix Inc and Goldman Sachs Group Inc, among others. - Reuters The DJIA rose 75.54 points, or 0.
KUALA LUMPUR (Oct 19): Shares of Pantech Group Holdings Bhd fell 3.45% in early trade today after its net profit plunged 51% to RM5.14 million or 0.84 sen per share for the second financial quarter ended Aug 31, 2016 (2QFY17), from RM10.43 million or 1.72 sen per share a year earlier.
KUALA LUMPUR (Oct 19): The FBM KLCI is expected to trend higher today and gear towards its 1,672 hurdle, in line with the overnight advance at most global markets.
KUALA LUMPUR (Oct 18): Based on corporate announcements and news flow today, companies that may be in focus tomorrow (Wednesday, Oct 19) could include: Top Glove Corp Bhd, Pasdec Holdings Bhd, Selangor Dredging Bhd, HeiTech Padu Bhd, Pantech Group Holdings Bhd, Tanjung Offshore Bhd and DBE Gurney Resources Bhd.
KUALA LUMPUR (July 22): The FBM KLCI is expected to come under pressure again today, in line with the overnight fall at most global markets, as well as the ripples created by the actions of the United States Department of Justice to sue on Wednesday to seize more than US$1 billion in assets they said were tied to money stolen from state fund 1Malaysia Development Bhd.
KUALA LUMPUR (July 21): Based on corporate announcements and newsflow today, companies in focus tomorrow (July 22) may include: CIMB, Gromutual, Pantech, Scomi Engineering, Public Bank and Sime Darby.
KUALA LUMPUR (April 14): Shares on Bursa Malaysia are expected to extend their gains today in line with the overnight uptrend at most global markets.
KUALA LUMPUR (April 13): Based on corporate announcements and news flow today, companies that will be in focus tomorrow (Thursday, April 14) may include: Muhibbah Engineering (M), Jaycorp, AirAsia X (AAX), PWF Consolidated, Green Packet, Ann Joo Resources, CCK Consolidated Holdings, Pantech Group Holdings, Edaran, YNH Property, Zhulian Corp and ECS ICT.
PILGRIM fund Lembaga Tabung Haji’s (LTH) portfolio of investments on the local bourse are a mixed bag of defensive and capital-intensive stocks, Bloomberg data shows.
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
2018-05-17 - Asif
Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...